1
|
Kang YJ, Oh SJ, Bae SY, Kim EK, Lee YJ, Park EH, Jeong J, Park HK, Suh YJ, Kim YS. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Sci Rep 2023; 13:11008. [PMID: 37420033 PMCID: PMC10328940 DOI: 10.1038/s41598-023-38200-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Accepted: 07/05/2023] [Indexed: 07/09/2023] Open
Abstract
The human epidermal growth factor receptor-2 (HER2) enriched subtype of breast cancer is associated with early recurrence, mostly within 5 years. However, anti-HER2 therapies have improved outcomes and their benefits persist in the long term. This study aimed to determine predictive factors for late survival in patients with HER2-positive breast cancer. We analyzed 20,672 patients with HER2-positive stage I-III breast cancer. The patients were divided into two groups based on a follow-up period of 60 months. The multivariate analysis of factors associated with poor overall survival included old age, advanced pathologic tumor size stage (pT), advanced pathologic regional lymph node stage (pN), high histological grade, presence of lymphatic and vascular invasion, and HR-negative status within 60 months. In the breast cancer-specific survival (BCSS) of the > 60 months follow-up group, the hazard ratios (HRa) based on pN-negative were 3.038, 3.722, and 4.877 in pN1 (p = 0.001), pN2 (p < 0.001), and pN3 (p < 0.001), respectively. Only pT4 level was statistically significant in the pT group (HRa, 4.528; p = 0.007). Age (HRa, 1.045, p < 0.001) and hormone receptor-positive status (HRa, 1.705, p = 0.022) were also associated to worse BCSS. Although lymphatic invasion was not significantly associated with BCSS, there was a tendency toward a relationship (p = 0.079) with worse BCSS. In HER2-positive breast cancer patients, node status had a more significant relationship with long-term prognosis than T stage. Patients with HER2-positive breast cancer who have T4 or node-positive should be considered for clinical observation and education beyond 5 years.
Collapse
Affiliation(s)
- Young-Joon Kang
- Department of Surgery, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea
| | - Se Jeong Oh
- Department of Surgery, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea
| | - Soo Youn Bae
- Department of Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
| | - Eun-Kyu Kim
- Department of Surgery, Seoul National University College of Medicine, Breast Care Center, Seoul National University Bundang Hospital, Seoul, Republic of Korea
| | - Young-Jin Lee
- Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Eun Hwa Park
- Department of Surgery, Dong-A University College of Medicine, Busan, South Korea
| | - Joon Jeong
- Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Heung Kyu Park
- Department of Surgery Breast Cancer Center, Gil Medical Center of Gachon University, Incheon, Republic of Korea
| | - Young Jin Suh
- Division of Breast and Thyroid Surgical Oncology, Department of Surgery, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Republic of Korea
| | - Yong-Seok Kim
- Department of Surgery, College of Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, 271, Cheonbo-ro, Uijeongbu-si, Gyeonggi-do, 11765, Republic of Korea.
| |
Collapse
|
2
|
Barboro P, Rubagotti A, Poddine S, Grillo F, Mastracci L, Boccardo F. The prognostic value of aspartate beta-hydroxylase in early breast cancer. Int J Biol Markers 2022; 37:328-335. [PMID: 35726161 DOI: 10.1177/03936155221108412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Aspartate beta-hydroxylase (ASPH) is a transmembrane protein involved in cancer progression, which has been shown to imply a worse prognosis in several solid tumors. The aim of the present study was to further investigate the prognostic value of ASPH in early breast cancer. METHODS ASPH expression was investigated through immunohistochemistry in a cohort of 153 breast cancer patients with long-term follow-up, and correlated with clinical-pathological features plus all-cause and breast-cancer-specific mortality. Appropriate statistics were utilized. RESULTS ASPH negatively correlated with all-cause and breast-cancer-specific mortality. CONCLUSIONS The results of this cohort study support the prognostic value of ASPH in early breast cancer.
Collapse
Affiliation(s)
- Paola Barboro
- Proteomic and Mass Spectrometry Unit, 9246IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy
| | - Alessandra Rubagotti
- Department of Health Sciences (DISSAL), School of Medicine, 9302University of Genoa, 16132 Genoa, Italy
| | - Silvia Poddine
- Department of Medicine and Medical Specialties (DIMI), School of Medicine, 9302University of Genoa, 16132, Genoa, Italy
| | - Federica Grillo
- Anatomic Pathology Unit, 9246IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.,Department of Surgical and Integrated Diagnostic Sciences (DISC), 9302University of Genoa, 16132, Genoa, Italy
| | - Luca Mastracci
- Anatomic Pathology Unit, 9246IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.,Department of Surgical and Integrated Diagnostic Sciences (DISC), 9302University of Genoa, 16132, Genoa, Italy
| | - Francesco Boccardo
- Department of Medicine and Medical Specialties (DIMI), School of Medicine, 9302University of Genoa, 16132, Genoa, Italy
| |
Collapse
|